Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew C Hsieh

Showing results (31-40 of 64) with videos related to

Pageof 7
Sort By:
Scientific Reports|February 26, 2021
A bladder cancer patient-derived xenograft displays aggressive growth dynamics in vivo and in organoid cultureElise Y Cai, Jose Garcia, Yuzhen Liu, et al.
Nature Communications|October 12, 2019
N<sup>6</sup>-methyladenosine mRNA marking promotes selective translation of regulons required for human erythropoiesisDaniel A Kuppers, Sonali Arora, Yiting Lim, et al.
Clinical Genitourinary Cancer|May 19, 2024
Adjuvant Chemotherapy and Survival After Radical Cystectomy in Histologic Subtype Bladder CancerElizabeth L Koehne, Dimitra R Bakaloudi, Fady Ghali, et al.
Clinical Genitourinary Cancer|June 21, 2023
Metastatic Bladder Cancer Expression and Subcellular Localization of Nectin-4 and Trop-2 in Variant Histology: A Rapid Autopsy StudyFady Ghali, Funda Vakar-Lopez, Martine P Roudier, et al.
Nature Communications|August 21, 2021
Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancersNinghui Mao, Zeda Zhang, Young Sun Lee, et al.
The Journal of Clinical Investigation|April 15, 2026
Therapeutic targeting of the eIF4E cap-binding domain reveals control of lineage fate in prostate cancerRashmi Mishra, Sihyeon Song, Dhruv Choradia, et al.
Science Translational Medicine|May 4, 2018
Development of a stress response therapy targeting aggressive prostate cancerHao G Nguyen, Crystal S Conn, Yae Kye, et al.
Urologic Oncology|April 17, 2018
Mechanistic target of rapamycin (MTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomyBrian R Winters, Funda Vakar-Lopez, Lisha Brown, et al.
Radiology|March 31, 2026
PSMA PET/CT-derived Tumor Volume for Predicting Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving <sup>177</sup>Lu-PSMA-617Alireza Ghodsi, Lukas Owens, Ridvan Arda Demirci, et al.
American Journal of Nuclear Medicine and Molecular Imaging|January 22, 2026
Results from a prospective registry of <sup>18</sup>F-Fluciclovine PET/CT use in prostate cancer management: a cautionary lesson for implementation of PSMA PETSteven Blinka, Risa L Wong, Sarah K Holt, et al.
Pageof 7

Showing results (31-40 of 64) with videos related to

Sort By:
Pageof 7
Scientific Reports|February 26, 2021
A bladder cancer patient-derived xenograft displays aggressive growth dynamics in vivo and in organoid cultureElise Y Cai, Jose Garcia, Yuzhen Liu, et al.
Nature Communications|October 12, 2019
N<sup>6</sup>-methyladenosine mRNA marking promotes selective translation of regulons required for human erythropoiesisDaniel A Kuppers, Sonali Arora, Yiting Lim, et al.
Clinical Genitourinary Cancer|May 19, 2024
Adjuvant Chemotherapy and Survival After Radical Cystectomy in Histologic Subtype Bladder CancerElizabeth L Koehne, Dimitra R Bakaloudi, Fady Ghali, et al.
Clinical Genitourinary Cancer|June 21, 2023
Metastatic Bladder Cancer Expression and Subcellular Localization of Nectin-4 and Trop-2 in Variant Histology: A Rapid Autopsy StudyFady Ghali, Funda Vakar-Lopez, Martine P Roudier, et al.
Nature Communications|August 21, 2021
Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancersNinghui Mao, Zeda Zhang, Young Sun Lee, et al.
The Journal of Clinical Investigation|April 15, 2026
Therapeutic targeting of the eIF4E cap-binding domain reveals control of lineage fate in prostate cancerRashmi Mishra, Sihyeon Song, Dhruv Choradia, et al.
Science Translational Medicine|May 4, 2018
Development of a stress response therapy targeting aggressive prostate cancerHao G Nguyen, Crystal S Conn, Yae Kye, et al.
Urologic Oncology|April 17, 2018
Mechanistic target of rapamycin (MTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomyBrian R Winters, Funda Vakar-Lopez, Lisha Brown, et al.
Radiology|March 31, 2026
PSMA PET/CT-derived Tumor Volume for Predicting Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving <sup>177</sup>Lu-PSMA-617Alireza Ghodsi, Lukas Owens, Ridvan Arda Demirci, et al.
American Journal of Nuclear Medicine and Molecular Imaging|January 22, 2026
Results from a prospective registry of <sup>18</sup>F-Fluciclovine PET/CT use in prostate cancer management: a cautionary lesson for implementation of PSMA PETSteven Blinka, Risa L Wong, Sarah K Holt, et al.
Pageof 7